Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 2—February 2021
Dispatch

SARS-CoV-2 Infections among Recent Organ Recipients, March–May 2020, United States

Jefferson M. JonesComments to Author , Ian Kracalik, Meenakshi M. Rana, Ann Nguyen, Brian C. Keller, Aaron Mishkin, Charles Hoopes, Thomas Kaleekal, Abhinav Humar, Juan Vilaro, Gene Im, Lou Smith, April Justice, Collette Leaumont, Stephen Lindstrom, Brett Whitaker, Ricardo M. La Hoz, Marian G. Michaels, David Klassen, Wendi Kuhnert, and Sridhar V. Basavaraju
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.M. Jones, I. Kracalik, C. Leaumont, S. Lindstrom, B. Whitaker, W. Kuhnert, S.V. Basavaraju); Icahn School of Medicine at Mount Sinai, New York, New York, USA (M.M. Rana, G. Im); University of Chicago, Chicago, Illinois, USA (A. Nguyen); The Ohio State University College of Medicine, Columbus, Ohio, USA (B.C. Keller); Temple University, Philadelphia, Pennsylvania, USA (A. Mishkin); University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA (C. Hoopes); Robert Wood Johnson University, New Brunswick, New Jersey, USA (T. Kaleekal); University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (A. Humar, M.G. Michaels); University of Florida College of Medicine, Gainesville, Florida, USA (J. Vilaro); New York State Department of Health, Albany, New York, USA (L. Smith); Ohio Department of Health, Columbus (A. Justice); University of Texas Southwestern Medical Center, Dallas, Texas, USA (R.M. La Hoz); United Network of Organ Sharing, Richmond, Virginia, USA (D. Klassen)

Cite This Article

Abstract

We conducted public health investigations of 8 organ transplant recipients who tested positive for severe acute respiratory syndrome coronavirus 2 infection. Findings suggest the most likely source of transmission was community or healthcare exposure, not the organ donor. Transplant centers should educate transplant candidates and recipients about infection prevention recommendations.

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been reported in organ transplant recipients, it is unclear whether SARS-CoV-2 can be transmitted from organ donors to recipients (1) and if transplant recipients are at increased risk for severe illness from coronavirus disease (COVID-19) from SARS-CoV-2 infection compared with immunocompetent patients (2). In March 2020, organ procurement organizations (OPOs) and transplant centers in the United States began to report potential donor-derived SARS-CoV-2 transmission to the Organ Procurement and Transplantation Network (OPTN) for investigation by the Disease Transmission Advisory Committee (DTAC). These cases were referred to the Centers for Disease Control and Prevention (CDC), a member of DTAC, to determine if SARS-CoV-2 transmission from a donor had occurred and, if so, to identify the transmission source, and characterize clinical outcomes in the organ recipients.

The Study

Current OPTN policy requires all US transplant centers and OPOs to report unanticipated potential donor-derived transmission events to the OPTN for investigation by DTAC. CDC coordinates investigations involving pathogens of special interest, including SARS-CoV-2 (Appendix).

For all reported potential donor-derived SARS-CoV-2 transmissions, CDC, OPO, or the transplant center staff reviewed medical records of organ donors and organ recipients. Recipients who initially tested positive for SARS-CoV-2 infection and triggered a notification to the OPTN of a potential donor-derived transmission were referred to as index recipients; recipients who shared a common donor with index recipients were referred to as co-recipients. CDC investigators asked OPO and index recipients’ hospital staff about potential exposures to SARS-CoV-2. Transplant hospital providers monitored organ recipients for symptoms of COVID-19 for >14 days following the transplant. Recipients who developed symptoms and, depending on hospital capacity, some asymptomatic recipients were tested for SARS-CoV-2 infection by a nucleic acid test (NAT). All donor serum were tested for the presence of SARS-CoV-2 RNA. Donor respiratory specimens were tested if available.

During March–May 2020, a total of 8 potential donor-derived transmission events involving 8 deceased donors and 31 recipients were reported to OPTN. Each event was reported because an individual transplant recipient (the index recipient) tested positive for SARS-CoV-2 infection (Table 1; Appendix). For all donors included in this study, the cause of death was determined to be a noninfectious etiology. Donor next of kin reported that no donors had had symptoms of COVID-19 or contact with persons known to have COVID-19. One donor was screened for SARS-CoV-2 infection by the OPO using a NAT before organ procurement and tested negative.

Among the 8 index recipients, 4 received lung, 2 received liver, and 2 received heart transplants (Table 2). The median age of index recipients was 65 years (range 37–75 years); the median duration from organ transplantation to symptom onset was 9 days (range 6–81 days). Seven (88%) index recipients experienced fever or lower respiratory tract symptoms. Seven index recipients required mechanical ventilation; 3 of them (2 liver recipients and 1 lung recipient) died. All index recipients had potential or confirmed community or healthcare exposure to persons infected with SARS-CoV-2.

Organs from the 8 deceased donors were transplanted into 31 recipients, including the 8 index recipients. Of the 23 co-recipients, 11 (48%) were tested for SARS-CoV-2 infection using a NAT; 1 tested positive 41 days after transplant. Twelve co-recipients were not tested because of absence of symptoms and need to conserve test supplies. Within 14 days after transplant, 3 co-recipients manifested symptoms related to COVID-19, but all tested negative.

Conclusions

The 8 potential donor-derived SARS-CoV-2 transmissions reported to the OPTN during March–May 2020 were referred to CDC for public health investigation. Although the source of transmission was not definitively established, the available evidence did not suggest transmission occurred from donors.

The risk for organ donor-derived SARS-CoV-2 transmission is unknown (1,3). Transmission of severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus, or SARS-CoV-2 from an organ or blood donor to a recipient has not been reported as of November 2020 (1). However, recent studies documented the presence of viral particles in organs of patients who had severe COVID-19 or died from COVID-19 (46). Infectious SARS-CoV-2 has been isolated from respiratory specimens, stool (7), and urine (8), suggesting transmissible virus might be present in extrapulmonary organs. Although these studies suggest that transplant transmission is plausible, the risk for SARS-CoV-2 transmission from extrapulmonary organs of asymptomatic infected deceased donors to organ recipients is unknown. Evidence suggests that the risk for viremia in persons with asymptomatic COVID-19 is low (9). However, OPOs should continue to evaluate donors for evidence of SARS-CoV-2 infection (10) because transmission of SARS-CoV-2 from organ donor to recipient might be possible and subsequent recipient infection might be severe; evaluating donors could also protect organ procurement and transplantation clinical teams. The American Society of Transplantation has recommended testing all donors by NAT since May 2020. No donors in this study had reported contact with persons with confirmed or suspected COVID-19.

COVID-19 has an estimated incubation period of 2–14 days (10), and all index recipients had confirmed or potential SARS-CoV-2 exposure during the 14 days before symptom onset or diagnosis. No co-recipients contracted COVID-19 within 14 days of transplant, providing further support that the donor was not the source of transmission. Transplant recipients and their healthcare providers should continue to take steps to reduce SARS-CoV-2 exposure.

Of the 8 index recipients in this study, 7 were intubated and 3 died. Seven of the index recipients received their COVID-19 diagnosis within 14 days of transplantation, which suggests that recipients of recent transplants may be at increased risk for severe disease compared with the general population (11) and possibly with organ recipients whose transplants were done months or years before SARS-CoV-2 infection (12). The advanced age of the index recipients in our study might have contributed to increased illness. Although some COVID-19 case series have suggested that organ transplant recipients are at higher risk for severe disease than the general population, others suggest that disease severity is similar (2,11). Data are sparse on the clinical severity of COVID-19 in recently transplanted organ recipients.

This study is subject to the following limitations. First, 7 of 8 donors were not tested for SARS-CoV-2 before transplant, and stored respiratory specimens were unavailable for retrospective testing. Although donor serum specimens were tested by NAT, limited performance and sensitivity data are available for this sample type using this test, and SARS-CoV-2 viremia is likely uncommon and intermittent (1). Second, donors and recipients might have had contact with unidentified persons with SARS-CoV-2 infection, including asymptomatic or presymptomatic persons (13). Asymptomatic SARS-CoV-2 infection might not have been detected in co-recipients given the low rate of testing (<50%). Finally, donor-derived SARS-CoV-2 transmission might not have been recognized by transplant clinicians and therefore not reported for investigation.

COVID-19 in the organ transplant recipients we report appears to have been community- or hospital-acquired. These findings suggest that organ transplant recipients, particularly in the immediate posttransplant period, might be at increased risk for severe COVID-19. Measures to limit household and healthcare-associated SARS-CoV-2 transmission to recipients should be implemented (10,14,15). All suspected donor-derived SARS-CoV-2 infections should be reported to the OPTN for further investigation.

Dr. Jones is a medical epidemiologist at the Office of Blood, Organ, and Other Tissue Safety, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention. Current research interests include infectious disease transmission through blood transfusion and organ transplantation and other medical product of human origin safety issues.

Top

Acknowledgment

We thank members of the Disease Transmission Advisory Committee and staff from the United Network of Organ Sharing staff, organ procurement organizations, and transplant centers for their assistance with the investigations.

Top

References

  1. Kates  OS, Fisher  CE, Rakita  RM, Reyes  JD, Limaye  AP. Use of SARS-CoV-2-infected deceased organ donors: Should we always “just say no?”. Am J Transplant. 2020;20:178794. DOIPubMed
  2. Molnar  MZ, Bhalla  A, Azhar  A, Tsujita  M, Talwar  M, Balaraman  V, et al.; STOP-COVID Investigators. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. Am J Transplant. 2020;20:306171. DOIPubMed
  3. Shah  MB, Lynch  RJ, El-Haddad  H, Doby  B, Brockmeier  D, Goldberg  DS. Utilization of deceased donors during a pandemic: argument against using SARS-CoV-2-positive donors. Am J Transplant. 2020;20:17959. DOIPubMed
  4. Puelles  VG, Lütgehetmann  M, Lindenmeyer  MT, Sperhake  JP, Wong  MN, Allweiss  L, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383:5902. DOIPubMed
  5. Wichmann  D, Sperhake  JP, Lütgehetmann  M, Steurer  S, Edler  C, Heinemann  A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. 2020;173:26877. DOIPubMed
  6. Lindner  D, Fitzek  A, Bräuninger  H, Aleshcheva  G, Edler  C, Meissner  K, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 2020;5:12815. DOIPubMed
  7. Xiao  F, Sun  J, Xu  Y, Li  F, Huang  X, Li  H, et al. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. Emerg Infect Dis. 2020;26:19202. DOIPubMed
  8. Sun  J, Zhu  A, Li  H, Zheng  K, Zhuang  Z, Chen  Z, et al. Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient. Emerg Microbes Infect. 2020;9:9913. DOIPubMed
  9. Chang  L, Zhao  L, Gong  H, Wang  L, Wang  L. Severe acute respiratory syndrome coronavirus 2 RNA detected in blood donations. Emerg Infect Dis. 2020;26:16313. DOIPubMed
  10. American Society of Transplantation. COVID-19 resources for transplant community. 2020 [cited 2020 June 24]. https://www.myast.org/covid-19-information
  11. Kates  OS, Haydel  BM, Florman  SS, Rana  MM, Chaudhry  ZS, Ramesh  MS, et al. UW COVID-19 SOT Study Team. COVID-19 in solid organ transplant: a multicenter cohort study. Clin Infect Dis. 2020;•••:ciaa1097. DOIPubMed
  12. Ravanan  R, Callaghan  CJ, Mumford  L, Ushiro-Lumb  I, Thorburn  D, Casey  J, et al. SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: A national cohort study. Am J Transplant. 2020;20:300818. DOIPubMed
  13. Burrer  SL, de Perio  MA, Hughes  MM, Kuhar  DT, Luckhaupt  SE, McDaniel  CJ, et al.; CDC COVID-19 Response Team. COVID-19 Response Team. Characteristics of health care personnel with COVID-19—United States, February 12–April 9, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:47781. DOIPubMed
  14. Centers for Disease Control and Prevention. If you are immunocompromised, protect yourself from COVID-19. May 14, 2020 [cited 2020 June 24]. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/immunocompromised.html
  15. Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic. 2019 [cited 2020 June 24]. https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html.

Top

Tables

Top

Cite This Article

DOI: 10.3201/eid2702.204046

Original Publication Date: December 16, 2020

Table of Contents – Volume 27, Number 2—February 2021

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Jefferson Jones, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop V18-4, Atlanta, GA 30329-4027, USA

Send To

10000 character(s) remaining.

Top

Page created: December 10, 2020
Page updated: January 24, 2021
Page reviewed: January 24, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external